Evidence map›Paper›PMID 41094333›Full record

ArticleOncology and therapy2025

Overlapping Extremes: An Analysis of Avelumab Maintenance and Pembrolizumab in Advanced Urothelial Carcinoma.

Martina Catalano, Irene de Gennaro Aquino, Ismaela Anna Vascotto, Adriana Guarino, Silvia Mancini, Laura Doni, Alexandra Paulet, Virginia Rossi, Roberta Giorgione, Gabriella Nesi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Martina CatalanoSection of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy.
Irene de Gennaro AquinoDepartment of Experimental and Clinical Medicine, University of Florence, 50134, Florence, Italy.
Ismaela Anna VascottoDepartment of Experimental and Clinical Medicine, University of Florence, 50134, Florence, Italy.
Adriana GuarinoDepartment of Experimental and Clinical Medicine, University of Florence, 50134, Florence, Italy.
Silvia ManciniDepartment of Experimental and Clinical Medicine, University of Florence, 50134, Florence, Italy.
Laura DoniClinical Oncology Unit, Careggi University Hospital, 50234, Florence, Italy.
Alexandra PauletDepartment of Experimental and Clinical Medicine, University of Florence, 50134, Florence, Italy.
Virginia RossiClinical Oncology Unit, Careggi University Hospital, 50234, Florence, Italy.
Roberta GiorgioneClinical Oncology Unit, Careggi University Hospital, 50234, Florence, Italy.
Gabriella NesiSection of Anatomic Pathology, Department of Health Sciences, University of Florence, 50139, Florence, Italy.
Lorenzo Antonuzzo *Department of Experimental and Clinical Medicine, University of Florence, 50134, Florence, Italy.
Giandomenico Roviello *Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy. giandomenico.roviello@unifi.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAvelumab and pembrolizumab are approved immune checkpoint inhibitors (ICIs) for advanced urothelial carcinoma (UC) that are used as maintenance and salvage therapies, respectively. The aim of this study was to highlight patterns of extreme response and support the development of biomarker-driven strategies to optimise patient selection and treatment sequencing.

methodsThis was a prospective study that included 79 patients with advanced UC treated with avelumab (n = 32) or pembrolizumab (n = 47) following platinum-based chemotherapy. Outcomes included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS).

resultsAvelumab was associated with a DCR of 84.4% and a complete response (CR) rate of 34.4%, while pembrolizumab was associated with a DCR of 55.3% and a CR rate of 12.8%. Progressive disease (PD) occurred in 15.6% and 44.7% of patients, respectively. Despite differences in treatment indications and timing, median PFS and OS in patients with CR and PD were surprisingly comparable across the two agents.

conclusionsThese findings suggest that extreme responses to ICIs in advanced UC-ranging from complete response to primary progression-may occur irrespective of treatment setting, underscoring the pivotal role of tumour-immune biology. Biomarker-driven strategies are needed to optimise patient selection.

trial registrationOBSERVE-UC study; registration ID: CEAVC 25351.

Indexed as

AvelumabBiomarkersImmunotherapyPembrolizumab

Identifiers

PMID41094333
PMCPMC12647452

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.